(Q24245541)

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Interrupting highly active antiretroviral therapy in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Predicting differential responses to structured treatment interruptions during HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

A prospective trial of structured treatment interruptions in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Biphasic decline of CD4 cell count during scheduled treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

HIV RNA in plasma rebounds within days during structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured treatment interruption in patients infected with HIV: a new approach to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

The concept of structured treatment interruptions in the management of patients with human immunodeficiency virus (HIV) disease: where are we currently?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Cytokine therapy or structured treatment interruptions in HIV infection: which is best?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured interruptions of therapy: looking for the best protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Bringing it all together: Lancet-Cochrane collaborate on systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured Treatment Interruption: Approaches and Risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Planned interruptions of anti-HIV treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Control of HIV despite the Discontinuation of Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured treatment interruptions in HIV/AIDS therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured treatment interruptions for the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured treatment interruptions in antiretroviral management of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured treatment interruptions to control HIV-1 and limit drug exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured Treatment Interruptions: A Risky Business

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

The strategy of immunologic control of HIV-1 with structured treatment interruptions (STIs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Structured treatment interruptions in HIV infection: benefit or disappointment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

Influence of Prior Structured Treatment Interruptions on the Length of Time without Antiretroviral Treatment in Chronically HIV-Infected Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006148

21 January 2018

Modern anti-HIV therapy.

1 reference

12 December 2020

Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads

1 reference

12 December 2020

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group

1 reference

12 December 2020

HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count

1 reference

12 December 2020

Treatment interruptions in the salvage setting: what have we learned?

1 reference

12 December 2020

Structured treatment interruptions to control HIV-1 infection

1 reference

12 December 2020

Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV Medicine

1 reference

12 December 2020

Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1?

1 reference

12 December 2020

CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy

1 reference

12 December 2020

Role of hydroxyurea during structured treatment interruptions.

1 reference

12 December 2020

Control of SIV rebound through structured treatment interruptions during early infection

1 reference

12 December 2020

Structured treatment interruptions and treatment intensification

1 reference

12 December 2020

Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.

1 reference

12 December 2020

Saving on drugs, reducing side-effects. Treatment interruptions benefit acute and chronic HIV infected patients

1 reference

12 December 2020

Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults

1 reference

12 December 2020

Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions

1 reference

12 December 2020

Supervised interruptions of antiretroviral therapy

1 reference

12 December 2020

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

1 reference

12 December 2020

Drug resistance mutations during structured treatment interruptions

1 reference

12 December 2020

[Structured interruptions in antiretroviral treatment: a new therapeutic strategy?]

1 reference

12 December 2020

1 reference

12 December 2020

HAART breaks: structured treatment interruptions

1 reference

12 December 2020

CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.

1 reference

12 December 2020

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients

1 reference

12 December 2020

[Anti-retroviral treatment interruptions in HIV-infected adults: causes, clinical, immunological and virological consequences]

1 reference

12 December 2020

Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study

1 reference

12 December 2020

Structured therapeutic interruptions: a review.

1 reference

12 December 2020

Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.

1 reference

12 December 2020

Structured treatment interruption in HIV infection.

1 reference

12 December 2020